cavatak
Biologicalexperimental
Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02316171)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Intercellular adhesion molecule-1BINDING AGENT
oncolytic virus
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02565992 | Phase 1 | Oct 1, 2015 | Viralytics |
| NCT02307149 | Phase 1 | Feb 1, 2015 | Providence Health & Services, Viralytics |
| NCT02316171 | Phase 1 | Dec 1, 2014 | Viralytics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viralytics | For profit | 3 | 3 | 1 | 2014 |
| Providence Health & Services | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1